Targeted Somatic Genomics for Solid Tumors
Focused Precision, Powered by Exome
GTx-200 is a targeted but powerful somatic testing solution that blends the depth of exome-based sequencing with the focus of up to 200 curated cancer genes. It detects key genomic alterations, mutational signatures, and biomarkers such as TMB and MSI, enabling clinicians to align treatment strategies with the tumor’s molecular profile.
Who is this Test for?
- Patients with solid tumors requiring biomarker-driven treatment planning.
- Clinicians seeking TMB, or MSI status to guide therapy decisions.
Variant Types Detected
Single Nucleotide Variants (SNVs)
- SNVs are single base changes between reference and the patient's genome.
Insertions and Deletions (Indels)
- Insertion
- Deletion
- Indels are small changes in DNA where a few bases are either added (insertion) or removed (deletion).
Copy Number Variants (CNVs)
- Amplification / Duplication
- Deletion
- Parts of DNA that are copied too many times or missing. This can make cancer genes overactive or silence protective genes.
Microsatellite Instability (MSI)
- Microsatellites are short, repeated DNA sequences (like “stutters” in the genetic code). Normally, cells fix mistakes in these repeats. If the DNA repair system is broken, the repeats become unstable. It’s an important marker for certain cancers and can predict response to immunotherapy.
Tumor Mutational Burden (TMB)
- TMB is the total number of mutations in a tumor’s DNA. A high TMB means the tumor has many genetic changes, which can make it easier for the immune system to recognize and attack it, and may predict response to immunotherapy.
What it Screens for
- All solid tumors
- Any gene of interest – fully customizable panel (up to 200 genes)
- Somatic mutations: SNVs, indels, CNVs
- Tumor mutational burden (TMB)
- Microsatellite instability (MSI)
- Actionable biomarkers for targeted therapy & clinical trials
Key Benefits
- Exome-level sensitivity: High-confidence variant detection.
- Comprehensive biomarker reporting: TMB, MSI in one test.
- Strategic decision-making: Supports precision treatment planning, trial matching, and translational research.
Turn Around Time
- 5-6 weeks
Do You Need a Doctor’s Request?
Yes. This test must be ordered by a physician, as the results can impact treatment decisions and require clinical interpretation. Your healthcare provider will determine if the test is appropriate based on your cancer type, stage, and treatment plan.
How it Works?
Step 1: FFPE Tissue Sample Collection
- Preserved tissue sample are collected from biopsies or surgeries.
- Stored in wax blocks, these samples keep DNA intact for testing.
Step 2: DNA Extraction
- We carefully extract the DNA from the sample.
- This DNA is what we need to study your genes.
Step 3: Library Preparation
- The DNA is prepared so it can be read by our sequencing machines.
- We add special tags and focus on the most important parts of your DNA.
Step 4: Next Generation Sequencing
- This is how we ‘’read’’ your DNA using advanced technology.
- It helps us find changes or mutations in your genes.
Step 5: Data Analysis
- Our proprietary software (D-KRYPT) helps us understand what the DNA changes mean.
- The results are derived from trusted medical databases.
Step 6: Personalized Patient Report
- You got a clear, easy-to-read report with important findings.
- Your doctor can use this to guide treatment or next steps.
Oncology Test Panels
Séquençage clinique
Solutions for Researchers
Prise en charge prénatale
Médecine régénérative
Healthcare
Agriculture
Precision Tumor Genomics, Delivered
GTx-200 provides focused somatic testing for solid tumors, analyzing up to 200 curated cancer genes with exome-level depth.
*All information is handled with strict confidentiality.
Learn if GTx-200 is Right for You
GTx-200™ helps uncover the genetic profile of your tumor, supporting your doctor in selecting the most effective treatments and identifying clinical trial options.
